Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CereTRec
- Development stage
- Preclinical
- Lead developer
- ChromoLogic
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Injectable
01
Overview
CereTRec is a preclinical nanoparticle-based therapeutic being developed by ChromoLogic for the treatment of Traumatic Brain Injury (TBI). The drug utilizes a Multi-Lamellar Vesicle (MLV) delivery system and is designed for injectable administration. While the specific molecular target and mechanism of action have not been publicly disclosed, the platform focuses on utilizing advanced drug delivery technologies to address the complex pathology of brain injuries.
Beyond the preview
Go deeper on CereTRec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CereTRec.